Apogee Therapeutics (NASDAQ:APGE) solidified its clinical roadmap for 2026 on Monday, reporting a year-end cash position of $902.9 million.
The San Francisco-based biotech, which is developing a suite of long-acting biologics for inflammatory and immunology (I&I) markets, confirmed that its current liquidity is sufficient to fund operations into the second half of 2028, covering several high-impact data readouts.
The company’s primary focus remains zumilokibart (APG777), an anti-IL-13 antibody designed with an extended half-life to allow for dosing as infrequent as once every three to six months.
Management confirmed that the 52-week maintenance data from the APEX Phase 2 Part A trial is expected this month, followed by the Part B 16-week induction readout in the second quarter of 2026.
If data remains positive, Apogee plans to initiate a global Phase 3 program for atopic dermatitis in the second half of the year.
Beyond its lead asset, Apogee is aggressively advancing its combination portfolio.
The company expects to report results from a Phase 1b head-to-head study in the second half of 2026 comparing APG279 (a combination of zumilokibart and an OX40L inhibitor) against the current standard of care, Dupixent.